Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teresa M Brooks

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2025
Antibody-Antigen Epitope Mapping by X-Ray CrystallographyAndrew Manion, Teresa M Brooks, Cory L Brooks
The Journal of Biological Chemistry|January 24, 2013
Lytic activity of the Vibrio cholerae type VI secretion toxin VgrG-3 is inhibited by the antitoxin TsaBTeresa M Brooks, Daniel Unterweger, Verena Bachmann, et al.
Journal of Bacteriology|September 28, 2011
VasH is a transcriptional regulator of the type VI secretion system functional in endemic and pandemic Vibrio choleraeMaya Kitaoka, Sarah T Miyata, Teresa M Brooks, et al.
Infection and Immunity|May 11, 2011
Vibrio cholerae requires the type VI secretion system virulence factor VasX to kill Dictyostelium discoideumSarah T Miyata, Maya Kitaoka, Teresa M Brooks, et al.
The Journal of Biological Chemistry|July 7, 2018
Structural basis of V<sub>H</sub>H-mediated neutralization of the food-borne pathogen <i>Listeria monocytogenes</i>Moeko Toride King, Ian Huh, Akhilesh Shenai, et al.
Glycobiology|December 28, 2016
Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigenMohammadreza Movahedin, Teresa M Brooks, Nitin T Supekar, et al.
Nature Communications|April 2, 2014
The Vibrio cholerae type VI secretion system employs diverse effector modules for intraspecific competitionDaniel Unterweger, Sarah T Miyata, Verena Bachmann, et al.
Plos One|October 31, 2012
Constitutive type VI secretion system expression gives Vibrio cholerae intra- and interspecific competitive advantagesDaniel Unterweger, Maya Kitaoka, Sarah T Miyata, et al.
Molecular Cancer Therapeutics|February 23, 2024
Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6Eric N Aguilar, Satish Sagar, Brandy R Murray, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2025
Antibody-Antigen Epitope Mapping by X-Ray CrystallographyAndrew Manion, Teresa M Brooks, Cory L Brooks
The Journal of Biological Chemistry|January 24, 2013
Lytic activity of the Vibrio cholerae type VI secretion toxin VgrG-3 is inhibited by the antitoxin TsaBTeresa M Brooks, Daniel Unterweger, Verena Bachmann, et al.
Journal of Bacteriology|September 28, 2011
VasH is a transcriptional regulator of the type VI secretion system functional in endemic and pandemic Vibrio choleraeMaya Kitaoka, Sarah T Miyata, Teresa M Brooks, et al.
Infection and Immunity|May 11, 2011
Vibrio cholerae requires the type VI secretion system virulence factor VasX to kill Dictyostelium discoideumSarah T Miyata, Maya Kitaoka, Teresa M Brooks, et al.
The Journal of Biological Chemistry|July 7, 2018
Structural basis of V<sub>H</sub>H-mediated neutralization of the food-borne pathogen <i>Listeria monocytogenes</i>Moeko Toride King, Ian Huh, Akhilesh Shenai, et al.
Glycobiology|December 28, 2016
Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigenMohammadreza Movahedin, Teresa M Brooks, Nitin T Supekar, et al.
Nature Communications|April 2, 2014
The Vibrio cholerae type VI secretion system employs diverse effector modules for intraspecific competitionDaniel Unterweger, Sarah T Miyata, Verena Bachmann, et al.
Plos One|October 31, 2012
Constitutive type VI secretion system expression gives Vibrio cholerae intra- and interspecific competitive advantagesDaniel Unterweger, Maya Kitaoka, Sarah T Miyata, et al.
Molecular Cancer Therapeutics|February 23, 2024
Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6Eric N Aguilar, Satish Sagar, Brandy R Murray, et al.
Pageof 1